A Tale of Two: 2-Year Outcomes of 2 Patients Undergoing Compassionate Use INTREPID and TricValve System Placement

Tricuspid regurgitation contributes to worsening heart failure symptoms, quality of life, and mortality. Medical therapy provides limited benefit, and surgical intervention in high-risk patients is associated with significant postoperative complications. Transcatheter tricuspid valve interventions are improving, but until recently, patient candidacy has been limited by the stringent inclusion and exclusion criteria of clinical trials. We present 2 cases of patients with severe tricuspid regurgitation treated in a compassionate use setting with transcatheter therapies. Patient 1 underwent TricValve (Products & Features) placement for mitigation of right-sided heart failure with at least 24 months free of hospitalization. Patient 2 underwent compassionate INTREPID valve (Medtronic) placement with at least 24 months free of heart failure-related hospitalization.